A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
NCT ID: NCT03336216
Last Updated: 2024-07-23
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
205 participants
INTERVENTIONAL
2017-12-18
2023-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
NCT03970252
BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
NCT03496662
Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer
NCT03697564
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
NCT02754726
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
NCT03184870
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A
Investigator choice of chemotherapy:
Gemcitabine/Nab-Paclitaxel (Abraxane®) or 5-Fluorouracil/Leucovorin/Irinotecan Liposome (ONIVYDE)
Nab-paclitaxel
specified does on specified days
Onivyde
specified dose on specified days
Fluorouracil
specified dose on specified days
Gemcitabine
specified dose on specified days
Leucovorin
Specified dose on specified days
Irinotecan Hydrochloride
Specified dose on specified days
Arm B
Cabiralizumab Q2W + Nivolumab Q4W
Cabiralizumab
specified dose on specified days
Nivolumab
specified dose on specified days
Arm C
Cabiralizumab Q2W + Nivolumab Q4W and Gemcitabine + Nab-Paclitaxel (Abraxane®) D1, 8 and 15 Q4W
Cabiralizumab
specified dose on specified days
Nab-paclitaxel
specified does on specified days
Nivolumab
specified dose on specified days
Gemcitabine
specified dose on specified days
Arm D
Cabiralizumab Q2W + Nivolumab Q4W and Oxaliplatin/5-Flurouracil/Leucovorin (FOLFOX) Q2W
Cabiralizumab
specified dose on specified days
Nivolumab
specified dose on specified days
Fluorouracil
specified dose on specified days
Oxaliplatin
specified dose on specified day
Leucovorin
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cabiralizumab
specified dose on specified days
Nab-paclitaxel
specified does on specified days
Onivyde
specified dose on specified days
Nivolumab
specified dose on specified days
Fluorouracil
specified dose on specified days
Gemcitabine
specified dose on specified days
Oxaliplatin
specified dose on specified day
Leucovorin
Specified dose on specified days
Irinotecan Hydrochloride
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ECOG Performance status 0-1
* Adequate organ functions
* Measurable disease
Exclusion Criteria
* Participants with active, known, or suspected autoimmune disease
* Uncontrolled or significant cardiovascular disease
* Prior exposure to selected immune cell-modulating antibody regimens
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Rochester, Minnesota
Phoenix, Arizona, United States
HonorHealth Research Institute
Scottsdale, Arizona, United States
Local Institution - 0007
Los Angeles, California, United States
University Of Colorado
Aurora, Colorado, United States
Florida Cancer Specialists - South
Fort Myers, Florida, United States
Florida Cancer Specialists - North
St. Petersburg, Florida, United States
Local Institution - 0001
Baltimore, Maryland, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Dana Farber Cancer Institute.
Boston, Massachusetts, United States
Local Institution - 0010
Boston, Massachusetts, United States
Washington University
St Louis, Missouri, United States
Local Institution - 0012
New York, New York, United States
Local Institution - 0005
New York, New York, United States
Local Institution - 0006
Philadelphia, Pennsylvania, United States
Local Institution - 0009
Pittsburgh, Pennsylvania, United States
Tennessee Oncology Chattanooga
Nashville, Tennessee, United States
Local Institution - 0013
Dallas, Texas, United States
Local Institution - 0011
Houston, Texas, United States
University Of Washington
Seattle, Washington, United States
Cross Cancer Institute
Edmonton, Alberta, Canada
Local Institution - 0037
Kingston, Ontario, Canada
Local Institution - 0035
Toronto, Ontario, Canada
Local Institution - 0041
Herlev, , Denmark
Local Institution - 0032
Heidelberg, , Germany
Local Institution - 0029
Mannheim, , Germany
Universitaetsklinikum Ulm
Ulm, , Germany
Local Institution - 0030
Würzburg, , Germany
Local Institution - 0025
Padua, , Italy
Local Institution - 0026
Roma, , Italy
Local Institution - 0023
Kashiwa-shi, Chiba, Japan
Local Institution - 0022
Chuo-ku, Tokyo, Japan
Local Institution - 0018
Seoul, , South Korea
Local Institution - 0017
Seoul, , South Korea
Local Institution - 0021
Barcelona, , Spain
Local Institution - 0019
Madrid, , Spain
Local Institution - 0020
Madrid, , Spain
Local Institution - 0033
Chur, , Switzerland
Local Institution - 0034
Lausanne, , Switzerland
Local Institution - 0024
Taipei, , Taiwan
Local Institution - 0031
Taipei, , Taiwan
Local Institution - 0016
Glasgow, Lanarkshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA025-006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.